We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

N4 Pharma plc (N4P) ORD GBP0.004

Sell:0.35p Buy:0.40p 0 Change: No change
Market closed |  Prices as at close on 27 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.35p
Buy:0.40p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 27 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:0.35p
Buy:0.40p
Change: No change
Market closed |  Prices as at close on 27 June 2025 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Share news, reports & tips

  • N4 Pharma reports narrower full-year operating loss

    6 June 2025 12:14

    (Sharecast News) - N4 Pharma reported a reduced operating loss of £1.22m for 2024 on Friday, down from £1.42m the prior year, as the biotech company continued to develop its proprietary Nuvec gene delivery...

  • N4 Pharma files for new UK patent

    4 December 2024 14:46

    (Sharecast News) - N4 Pharma, a pharmaceutical company specializing in RNA therapeutics, announced the filing of a new patent with the UK patent office on Wednesday, for its oral anti-inflammatory treatment...

  • N4 Pharma reports positive progress with SRI collaboration

    20 August 2024 10:10

    (Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on the development of Nuvec, a novel delivery system for cancer treatments, gene therapy, and vaccines, updated the market on its...

  • N4 Pharma shares tank after £0.6m fundraise

    7 June 2024 11:06

    (Sharecast News) - Shares in small-cap pharma group N4 Pharma sank on Friday after the company announced a share placing and subscription to raise £630,000.

  • N4 Pharma shares jump on latest Nuvec developments

    15 February 2024 13:17

    (Sharecast News) - N4 Pharma announced a significant advancement in the development of Nuvec, an innovative delivery system tailored for cancer treatments, gene therapy, and vaccines, on Thursday.

  • N4 Pharma's Nuvec granted patent in India

    19 January 2024 13:00

    (Sharecast News) - N4 Pharma, a pharmaceutical company developing the cancer vaccine delivery system Nuvec, announced on Friday that it has received confirmation from the University of Queensland regarding...

  • N4 Pharma subsidiary agrees work programme for glaucoma treatment

    16 January 2024 14:05

    (Sharecast News) - N4 Pharma announced a significant development through its subsidiary Nanogenics on Tuesday, after Nanogenics inked a contract to initiate the formulation and sequence selection work for...

  • N4 Pharma reports progress in Nuvec clinical research

    8 January 2024 12:30

    (Sharecast News) - Pharmaceutical delivery system developer N4 Pharma reported significant progress in its research efforts to enhance viral vector performance using Nuvec on Monday.

  • N4 Pharma upbeat on recent Nuvec developments

    18 December 2023 11:17

    (Sharecast News) - N4 Pharma updated the market on Monday on its ongoing research efforts related to Nuvec, its delivery system designed for cancer treatments and vaccines.

  • N4 Pharma posts optimistic Nuvec research update

    7 December 2023 13:20

    (Sharecast News) - N4 Pharma, a specialist pharmaceutical company focused on developing the Nuvec delivery system for cancer treatments and vaccines, issued an optimistic update on its ongoing in-vitro siRNA...

  • N4 Pharma picks up controlling interest in Nanogenics

    28 September 2023 13:28

    (Sharecast News) - Pharmaceutical firm N4 Pharma announced the acquisition of a controlling interest in Nanogenics on Thursday.

  • N4 Pharma reports progress with siRNA work

    18 April 2023 13:13

    (Sharecast News) - N4 Pharma updated the market on its ongoing research work on gene-silencing technology siRNA on Tuesday.

Company announcements Announcements


Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.

© Digital Look Ltd 1998-2025. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.